Creative Biolabs provides custom-specific research and services due to our years of experience gained in our several successful projects. We can provide individual services of cardiovascular drugs screening and safety evaluation based on our advanced STEMOD™ platform.
Cardiovascular disease is a leading cause of morbidity and mortality worldwide. The diseases are chronic, complex, and the result of sophisticated interactions between genetics and environment involving multiple cell types and a host of systemic factors. Cardiovascular diseases remain a major challenge for modern drug discovery, and there is an urgent need for better treatment options. To address cardiovascular toxicity, novel approaches are needed to fill the gap and make drug discovery affordable and effective. Besides in vivo animal models, in vitro models have been recently proposed to mimic the physiological conditions of the heart and vasculature. Stem cells are a valuable tool in the drug discovery process. Stem cells have the possibility of isolating from a wide spectrum of tissues and growing in vitro and the ability to differentiate into a number of specialized cell types, and eventually serve as iPSC-derived in vitro models. These features of stem cells allow drug screening to be directed towards stem cell self-renewal, proliferation, differentiation, and various disease-related drug discovery programs.
Fig.1 Implementation of hPSC-CMs in cardiac research. 1
Extensive pharmacological studies have shown that stem cells could accelerate drug screening, enable more accurate prediction of the human cardiac response to pharmacotherapy, and provide tools for personalized drug screening assays to timely and accurately predict a patient's drug response. Creative Biolabs provides a high throughput platform for cardiovascular drug discovery, screening, validation, and safety evaluation based on our STEMOD™ stem cell model. This new methodology presents a fast, cost-effective, sensitive, and reliable method for performing cardiovascular drug screening in a timely and cost-effective manner. In addition, our team will work with you to custom design the best-fit solutions to enable smarter decisions and select the best drugs to move forward.
Cardiovascular toxicity is a major limiting factor in cardiovascular drug development, so it requires multiple cost-effective models to perform the safety evaluation. In this area, the STEMOD™ platform at Creative Biolabs allows direct assessment of the effects, side effects, and toxicity of drugs from many aspects, including analysis of the contractility, contraction frequency, vitality, contraction frequency regularity of cardiomyocytes, and site detection. We are dedicated to assisting in iPSC for drug cardiotoxicity screening, which will ultimately reduce cost, save time in the preclinical phase of the development of your projects.
The stem cell-based model is an excellent tool for drug discovery and toxicological studies. As a world-leading service provider in the field of MSC generation, the experienced scientists at Creative Biolabs are devoted to offering STEMOD™ based cardiovascular drugs screening and safety evaluation for our customers. Our state-of-the-art technologies and highly qualified personnel guarantee that we can deliver maximum quality and flexibility in all phases. Please contact us today to discuss your project with a technical specialist.
This service is tailored for researchers in the field of drug discovery, providing a robust framework to assess drug efficacy and safety prior to clinical trials. We utilize advanced stem cell technology to generate cardiovascular cell types, including cardiomyocytes, endothelial cells, and fibroblasts. Key components of the service include:
Our service is ideal for pharmaceutical and biotech companies in the early stages of drug development, supports academic institutions conducting research on cardiovascular diseases and drug mechanisms and provides opportunities for collaboration with industry partners for joint research projects.
Below are the findings presented in the article related to stem cells as in vitro models for cardiovascular drug discovery.
Mengcheng Shen, PhD et al. reported a stepwise approach for generating first-of-its-kind cardiac pericytes (CPs) from iPSCs that are transcriptionally and functionally similar to primary CPs. To obtain pure iPSC-CP, they first stepwise generated epicardial pericytes (EPI), the primary progenitor cells that give rise to CP.
They used quantitative reverse transcription-polymerase chain reaction to confirm comparable expression levels of cellular markers between primary and iPSC-CP, examined the relative cell contractility of iPSC-CP versus iPSC smooth muscle cells, and tested the proangiogenic potential of iPSC-CP. The results suggest that their human iPSC-CP represents a novel model system that is critical for understanding coronary microvascular dysfunction.
Fig. 2 Phenotypic characterization and functional assessment of iPSC pericardial cells.2
References
For Research Use Only. Not For Clinical Use.
